<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444001</url>
  </required_header>
  <id_info>
    <org_study_id>PPR01</org_study_id>
    <nct_id>NCT01444001</nct_id>
  </id_info>
  <brief_title>Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety, tolerability, and immunogenicity of three&#xD;
      doses of an investigational pneumococcal vaccine in healthy adult volunteers.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each volunteer participant will receive two injections with one of three vaccine doses,&#xD;
      administered on Day 0 and Day 30, in a dose-ascending manner, pending safety review at each&#xD;
      dose level. All participants will be monitored for safety for 30 days after each injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of solicited injection site reactions, solicited systemic reactions, unsolicited systemic reactions, and serious adverse events occurring throughout the trial</measure>
    <time_frame>Day 0 up to Day 60 post vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of pneumococcal vaccine after 2 vaccinations</measure>
    <time_frame>Day 0 and 30 days post vaccination</time_frame>
    <description>Evaluation of immune responses to antigen component of the investigational vaccine by enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Pneumococcal Pneumonia</condition>
  <arm_group>
    <arm_group_label>Pneumococcal Vaccine Dose 1 (Low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumococcal Vaccine Dose 2 (Middle dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumococcal Vaccine Dose 3 (High dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Vaccine</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Pneumococcal Vaccine Dose 1 (Low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Vaccine</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Pneumococcal Vaccine Dose 2 (Middle dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Vaccine</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Pneumococcal Vaccine Dose 3 (High dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 50 years on the day of inclusion&#xD;
&#xD;
          -  Healthy, as determined by medical history and clinical examination&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
          -  For a woman, inability to bear a child or negative urine pregnancy test at each&#xD;
             vaccination visit&#xD;
&#xD;
          -  For a woman of child-bearing potential: use of two medically acceptable, effective&#xD;
             methods of contraception (oral contraceptive, intrauterine device, diaphragm,&#xD;
             spermicide, or condom) or abstinence throughout the study participation starting at&#xD;
             least 30 days prior to the first vaccination up to at least 30 days after the last&#xD;
             vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic,&#xD;
             gastrointestinal, psychiatric, or other organ system) that could interfere with trial&#xD;
             conduct or and/or raise a safety concern&#xD;
&#xD;
          -  For a woman, breast-feeding&#xD;
&#xD;
          -  Participation in another clinical trial in the 30 days preceding the first trial&#xD;
             vaccination&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer&#xD;
             chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic&#xD;
             corticosteroids therapy&#xD;
&#xD;
          -  Systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or a vaccine containing the same&#xD;
             substances&#xD;
&#xD;
          -  Current abuse of alcohol or drug addiction that may interfere with the subject's&#xD;
             ability to comply with trial procedures&#xD;
&#xD;
          -  Blood or blood-derived products received in the past 3 months&#xD;
&#xD;
          -  Any vaccination in the 30 days preceding the first trial vaccination&#xD;
&#xD;
          -  Vaccination planned in the 30 days following any trial vaccination&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C seropositivity&#xD;
&#xD;
          -  Known thrombocytopenia or bleeding disorder contraindicating intramuscular (IM)&#xD;
             vaccination&#xD;
&#xD;
          -  Subject deprived of freedom by an administrative or court order, or in an emergency&#xD;
             setting, or hospitalized without his/her consent&#xD;
&#xD;
          -  Febrile illness (≥ 38.0°C [or 100.4°F]) within 72 hours of inclusion/vaccination&#xD;
&#xD;
          -  Previous vaccination in the preceding 5 years against pneumococcal disease with&#xD;
             another vaccine&#xD;
&#xD;
          -  History of pneumococcal infection (confirmed either clinically, serologically, or&#xD;
             microbiologically) within 5 years&#xD;
&#xD;
          -  Subject at high risk of pneumococcal infection during the trial&#xD;
&#xD;
          -  Subjects living in a household with children &lt; 5 years of age&#xD;
&#xD;
          -  Antibiotic usage or upper or lower respiratory tract infection within one week before&#xD;
             any blood draw for immunogenicity (Visits 1, 3, and 5).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Allschwil</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal Infections</keyword>
  <keyword>Pneumococcal Vaccines</keyword>
  <keyword>pneumococcal protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

